
WHAT IS CLAIMED IS:

1. A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof,

wherein

Y is CHR^5 or NR^6;

Z is CH, CR^3, or N;

n is 0, 1, 2, or 3;

R^1 is $–O–L–N(R^7)_2$ or optionally substituted, four-memberred, saturated *N*-heterocyclyl;

R^2 is $C_{1\text{-}3}$ alkyl;

each R^3 is independently halogen or optionally substituted $C_{1\text{-}3}$ alkyl;

R^4 is optionally substituted alkyl;

R^5 is hydrogen, optionally substituted $C_{1\text{-}3}$ alkyl, or benzyloxy;


R^6 is optionally substituted $C_{1\text{-}3}$ alkyl;

each R^7 is independently H or optionally substituted $C_{1\text{-}3}$ alkyl; and

L is optionally substituted ethylene.

2 The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein n is 1.

3 The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (IA):



(IA)


or a pharmaceutically acceptable salt thereof.

4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R^3 is halogen.

5. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein halogen is fluorine.

6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein n is 0.

7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (IB):



(IB)

or a pharmaceutically acceptable salt thereof.

8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R^1 is $–O–L–N(R^7)_2$.

9. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein one R^7 is H, and the remaining R^7 is optionally C_{1-3} alkyl.

10. The compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein at least one R^7 is isopropyl.

11. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein R^2 is methyl, ethyl, or isopropyl.

12. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein R^2 is methyl.

13. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein R^4 is methyl.

14. The compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein Y is CHR^5.

15. The compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein R^5 is hydrogen.

16. The compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein R^5 is optionally substituted C_{1-3} alkyl










17. The compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein R^5 is benzyloxy.

18. The compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein Y is NR^6.

19. The compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, wherein R^6 is optionally substituted C_3 alkyl.


20. The compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, wherein R^6 is isopropyl.

21. A compound selected from the group consisting of:


,

,

,

,

,

,

,

,

,


and pharmaceutically acceptable salts thereof.

22. A compound of the following structure:




or a pharmaceutically acceptable salt thereof.

23. A compound of the following structure:



or a pharmaceutically acceptable salt thereof.

24. A compound of the following structure:



or a pharmaceutically acceptable salt thereof.

25. A pharmaceutical composition comprising the compound of any one of claims 1 to 24 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

26. ~~A method of~~Use of a therapeutically effective amount of the compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 25 in the manufacture of a medicament for treating an oncological disease~~, comprising administering a therapeutically effective amount of the compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 25 to~~ in a patient in need thereof.

27. The ~~method~~ use of claim 26, wherein the patient is one who is receiving radiotherapy.

28. The ~~method~~ use of claim 27, wherein the compound or the pharmaceutical composition is to be administered to the patient concomitantly with the radiotherapy.

29. The ~~method~~ use of claim 27, wherein the compound or the pharmaceutical composition is to be administered to the patient before radiotherapy.

30. The ~~method~~ use of claim 27, wherein the compound or the pharmaceutical composition is to be administered to the patient after radiotherapy.

31. The ~~method~~ use of any one of claims 27 to 30, wherein the radiotherapy comprises external, internal, brachytherapy, or systemic exposure.

32. The ~~method~~ use of any one of claims 27 to 31, wherein the radiotherapy comprises ~~administering~~ an antibody radionuclide conjugate.

33. The ~~method~~ use of any one of claims 26 to 32, wherein the patient is one who is receiving an anti-tumor agent.

34. The ~~method~~ use of claim 33, wherein the anti-tumor agent is cisplatin, oxaliplatin, carboplatin, valrubicin, idarubicin, calicheamicin, or a PARP inhibitor.

35. The ~~method~~ use of claim 34, wherein the anti-tumor agent is an anti-tumor biological agent or an anti-tumor immunotherapeutic agent.

36. The ~~method~~ use of any one of claims 33 to 35, wherein the compound or the pharmaceutical composition is to be administered to the patient concomitantly with the anti-tumor agent.

37. The ~~method~~ use of any one of claims 33 to 35, wherein the compound or the pharmaceutical composition is to be administered to the patient before the anti-tumor agent.

38. The ~~method~~ use of any one of claims 33 to 35, wherein the compound or the pharmaceutical composition is to be administered to the patient after the anti-tumor agent.

39. The ~~method~~ use of any one of claims 26 to 38, wherein the oncological disease is a brain cancer, bladder cancer, breast cancer, central nervous system cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, gastrointestinal stromal tumor, gastric cancer, head and neck cancer, buccal cancer, cancer of the mouth, hepatocellular cancer, lung cancer, melanoma, Merkel cell carcinoma, mesothelioma, nasopharyngeal cancer, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, salivary gland cancer, sarcomas, testicular cancer, urothelial cancer, vulvar cancer, or Wilm's tumor.

40. The ~~method~~ use of any one of claims 26 to 38, wherein the oncological disease is a breast cancer, lung cancer, head and neck cancer, pancreatic cancer, rectal cancer, glioblastoma, hepatocellular carcinoma, cholangiocarcinoma, metastic liver lesions, melanoma, bone sarcoma, soft tissue sarcoma, endometrial cancer, cervical cancer, prostate cancer, or Merkel cell carcinoma.